Photo by Josh Hedges/Zuffa LLC/Zuffa LLC via Getty Images
Ultimate Fighting Championship (UFC) middleweight veteran, CB Dollaway, was recently suspended two years by United States Anti-Doping Agency (UFC) after testing positive for anastrozole, as well as clomiphene, in a pair of out-of-competition drug tests collected in Dec. of 2018 and Feb. of 2019.
In addition, the 17-9 “Doberman” was zapped for an over-the-limit intravenous (IV) infusion, though USADA will treat all three offenses as one violation, leaving Dollaway, 36, with only a two-year suspension, common for most first offenders.
His return date is currently set for Dec. 18, 2020.
“In light of the recent decision made by USADA to issue me a two year sanction, I want it to be very clear that I did not knowingly nor intentionally take any performance enhancing drugs,” Dollaway told his Instagram followers. “As many people close to me are aware, I suffered a serious back injury in 2016. With my insurance capped out, I needed to find alternative solution if I wanted to continue to compete in mixed martial arts.”
Clomiphene is the same substance that landed Jon Jones in hot water back in summer 2016. It also came up positive when USADA took Brock Lesnar to the cleaners in the wake of his Mark Hunt win that same year.
“I traveled to Mexico to have a stem cell procedure done and ended up coming into contact with the mentioned substances. I am sorry to let my friends, family and fans down. I want to personally thank Donna Marcolini, the VP of health and performance of the UFC, for her assistance and for believing in me. I will take this time to continue working on my health and hopefully be ready to come back in 2020 as a healthy athlete/fighter for the first time since 2016.”
Assuming he doesn’t find himself on season two of “When Elevators Attack.”